Lupus Nephritis Clinical Trials in Philadelphia, Pennsylvania

5 studies are recruiting for lupus nephritis in Philadelphia, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. VIBRANT: VIB4920 for Active Lupus Nephritis

   This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Temple University, Lewis Katz School of Medicine, Department of Medicine: Nephrology, Philadelphia, Pennsylvania

   Locations

   17 in total

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT05201469 on ClinicalTrials.gov

2. A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants

   This phase II, randomized, double-blind, placebo-controlled study is designed to evaluate the safety, efficacy and pharmacokinetics (PK) of obinutuzumab in adolescent participants (AP) aged 12 to less than 18 with biopsy-confirmed proliferative lupus nephritis (LN). It will also evaluate open label…

   Stage

   Phase 2

   Ages

   5 to 17

   Site

   Chldren?s Hospital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   43 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT05039619 on ClinicalTrials.gov

3. RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

   RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   Children's Hospital of Philadelphia, Philadelphia, Pennsylvania

   Locations

   23 in total

   Run by

   Cabaletta Bio

   See if you can join NCT06121297 on ClinicalTrials.gov

4. Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

   The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.

   Stage

   Phase 2

   Ages

   18 to 100

   Site

   Temple University, Philadelphia, Pennsylvania

   Locations

   103 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT05268289 on ClinicalTrials.gov

5. A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

   This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants with moderate-to-severe active systemic lupus erythematosus (SLE) with or without nephritis, antine…

   Stage

   Phase 1

   Ages

   12 to 70

   Site

   Jefferson Einstein Hospital Philadelphia, Philadelphia, Pennsylvania

   Locations

   21 in total

   Run by

   Fate Therapeutics

   See if you can join NCT06308978 on ClinicalTrials.gov